Two Kinds of Radix Salviae Miltiorrhizae Injection for Angina Pectoris: A Systematic Review and Pharmacoeconomics Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 SHI Ya-fei ¹ ^# ,  YAN Hui ¹ ^# ,  SUN Shi-guang ¹ , WANG Rui ² , SUN Xiao-di ² , LI Yang ¹ , WANG Su-hui ²

1. Department of the Second Outpatient Services, The Military General Hospital of Beijing PLA, Beijing 100700, China;
2. Department of Pharmacy, The Military General Hospital of Beijing PLA, Beijing 100700, China;

Corresponding author：

SUN Shi-guang, Email: ssgbzcg@163.com

Keywords：

Salvianolate; Danshen injection; Angina; Pharmacoeconomics; Systematic review; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20140050

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the effectiveness and safety of salvianolate injection and Danshen injection for patients with angina pectoris, and evaluate the cost of drug. Methods We electronically searched databases including PubMed, CENTRAL (Issue 4, 2013), CNKI, VIP and WanFang Data (2004.1 to 2013.5) for the randomized controlled trials (RCTs) on the comparison between salvianolate injection and Danshen injection for angina pectoris from January 2004 to May 2013. Relevant journals and conference proceedings were also manually retrieved. Two reviewers independently screened literature in accordance with the inclusion and exclusion criteria, extracted the data and assess the methodological quality of included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 10 RCTs involving 1 196 patients were included. The results of meta-analysis showed that, salvianolate injection was obviously superior to Danshen injection in the effectiveness (OR=3.79, 95%CI 2.78 to 5.17, P < 0.000 01) and safety (OR=0.24, 95%CI 0.09 to 0.64, P=0.004), but lack of economic advantages in the treatment of the angina pectoris diseases. Conclusion Current evidence indicates that, salvianolate injection is a safe and effective scheme for angina pectoris, and Danshen injection is considered as a economic method. Because of the limited quantity and quality of currently-available research, the aforementioned conclusion should be verified by strictly-designed and large-scale sample RCTs.

Citation： SHI Ya-fei, YAN Hui, SUN Shi-guang, WANG Rui, SUN Xiao-di, LI Yang, WANG Su-hui. Two Kinds of Radix Salviae Miltiorrhizae Injection for Angina Pectoris: A Systematic Review and Pharmacoeconomics Analysis. Chinese Journal of Evidence-Based Medicine, 2014, 14(3): 287-291. doi: 10.7507/1672-2531.20140050 Copy

1.	杨兴华, 刘国安.中医药治疗冠心病心绞痛的研究进展.中医临床研究, 2011, 3(20):120-122.
2.	赵琼, 任大伟, 杨瑞花, 等.丹参不同产地加工方法对丹参多酚酸盐质量的影响.中华中医药杂志, 2013, 28(3):645-648.
3.	虞敏, 张光辉.丹参注射液治疗冠心病心绞痛的临床观察.海峡药学, 2012, 24(6):126-127.
4.	国际心脏病学会和协会及世界卫生组织命名标准联合专题组.缺血性心脏病的命名及诊断标准.中华心血管病杂志, 1981, 9(1):75.
5.	Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collbration, 2011. Available at:www.Cochrane-handbook.org.
6.	颜平, 罗心平, 施海明, 等.丹参多酚酸治疗心绞痛患者的临床疗效及对血小板功能的影响.介入放射学杂志, 2004, 12(2):55-59.
7.	苗阳, 高铸烨, 徐凤芹, 等.丹参多酚酸盐治疗冠心病心绞痛(心血瘀阻证)的临床观察.中药研究与信息, 2005, 7(10):23-26.
8.	郑建文.注射用丹参多酚酸盐治疗冠心病45例.中西医结合心脑血管病杂志, 2006, 4(12):1039-1040.
9.	李湘平, 尹桃.丹参多酚酸盐注射液治疗冠心病的疗效观察.中国现代医学杂志, 2010, 20(4):619-621, 624.
10.	周菁, 罗海明, 姚春梅.丹参多酚酸盐治疗30例不稳定型心绞痛患者临床疗效观察. 2011, (1):16-17.
11.	唐召力, 覃碧云, 滕秋叶, 等.丹参多酚酸盐与丹参注射液对不稳定型心绞痛氧化修饰低密度脂蛋白、血友病因子和超敏C反应蛋白的作用比较.临床荟萃, 2012, 27(17):1495-1497.
12.	赵业清.丹参多酚酸盐注射液治疗冠心病心绞痛65例临床观察.临床合理用药, 2012, 5(2B):70-71.
13.	王保成, 温超英.丹参多酚酸盐治疗冠心病不稳定心绞痛临床研究.中医学报, 2009, 24(145):58-59.
14.	姜奥.注射用丹参多酚酸盐治疗冠心病心绞痛(心血疲阻型)的Ⅱ期临床研究.成都中医药大学, 2005:4-01.
15.	金惠玲.注射用丹参多酚酸盐治疗稳定型心绞痛(心血癖阻型)的Ⅲ期临床研究.成都中医药大学, 2006:4-01.
16.	刘丽娟, 钱莉玲.卫生经济学评价及其在新生儿学科中的应用.中国循证儿科杂志, 2012(6):70-76.
17.	沈建通, 杨晓妍, 李幼平, 等.我国示范乡镇卫生院基本药物循证评价与遴选之十一:冠心病.中国循证医学杂志, 2012, 12(8):948-957.
18.	宋燕青, 徐向阳, 孙仁弟.注射用丹参多酚酸盐的临床应用概述.药物流行病学杂志, 2012, 21(8):404-407.
19.	彭丽虹, 余正, 盛春雷.丹红注射液治疗冠心病心绞痛随机对照试验的系统评价.中国循证医学杂志, 2011, 11(1):57-63.
20.	李然.中药注射剂安全性"四性".中国医院用药评价与分析, 2012(5):92-95.

1. 杨兴华, 刘国安.中医药治疗冠心病心绞痛的研究进展.中医临床研究, 2011, 3(20):120-122.
2. 赵琼, 任大伟, 杨瑞花, 等.丹参不同产地加工方法对丹参多酚酸盐质量的影响.中华中医药杂志, 2013, 28(3):645-648.
3. 虞敏, 张光辉.丹参注射液治疗冠心病心绞痛的临床观察.海峡药学, 2012, 24(6):126-127.
4. 国际心脏病学会和协会及世界卫生组织命名标准联合专题组.缺血性心脏病的命名及诊断标准.中华心血管病杂志, 1981, 9(1):75.
5. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collbration, 2011. Available at:www.Cochrane-handbook.org.
6. 颜平, 罗心平, 施海明, 等.丹参多酚酸治疗心绞痛患者的临床疗效及对血小板功能的影响.介入放射学杂志, 2004, 12(2):55-59.
7. 苗阳, 高铸烨, 徐凤芹, 等.丹参多酚酸盐治疗冠心病心绞痛(心血瘀阻证)的临床观察.中药研究与信息, 2005, 7(10):23-26.
8. 郑建文.注射用丹参多酚酸盐治疗冠心病45例.中西医结合心脑血管病杂志, 2006, 4(12):1039-1040.
9. 李湘平, 尹桃.丹参多酚酸盐注射液治疗冠心病的疗效观察.中国现代医学杂志, 2010, 20(4):619-621, 624.
10. 周菁, 罗海明, 姚春梅.丹参多酚酸盐治疗30例不稳定型心绞痛患者临床疗效观察. 2011, (1):16-17.
11. 唐召力, 覃碧云, 滕秋叶, 等.丹参多酚酸盐与丹参注射液对不稳定型心绞痛氧化修饰低密度脂蛋白、血友病因子和超敏C反应蛋白的作用比较.临床荟萃, 2012, 27(17):1495-1497.
12. 赵业清.丹参多酚酸盐注射液治疗冠心病心绞痛65例临床观察.临床合理用药, 2012, 5(2B):70-71.
13. 王保成, 温超英.丹参多酚酸盐治疗冠心病不稳定心绞痛临床研究.中医学报, 2009, 24(145):58-59.
14. 姜奥.注射用丹参多酚酸盐治疗冠心病心绞痛(心血疲阻型)的Ⅱ期临床研究.成都中医药大学, 2005:4-01.
15. 金惠玲.注射用丹参多酚酸盐治疗稳定型心绞痛(心血癖阻型)的Ⅲ期临床研究.成都中医药大学, 2006:4-01.
16. 刘丽娟, 钱莉玲.卫生经济学评价及其在新生儿学科中的应用.中国循证儿科杂志, 2012(6):70-76.
17. 沈建通, 杨晓妍, 李幼平, 等.我国示范乡镇卫生院基本药物循证评价与遴选之十一:冠心病.中国循证医学杂志, 2012, 12(8):948-957.
18. 宋燕青, 徐向阳, 孙仁弟.注射用丹参多酚酸盐的临床应用概述.药物流行病学杂志, 2012, 21(8):404-407.
19. 彭丽虹, 余正, 盛春雷.丹红注射液治疗冠心病心绞痛随机对照试验的系统评价.中国循证医学杂志, 2011, 11(1):57-63.
20. 李然.中药注射剂安全性"四性".中国医院用药评价与分析, 2012(5):92-95.

Chinese Journal of Evidence-Based Medicine

Two Kinds of Radix Salviae Miltiorrhizae Injection for Angina Pectoris: A Systematic Review and Pharmacoeconomics Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content